2-Arachidonyl glyceryl ether (Czech Wikipedia)

Analysis of information sources in references of the Wikipedia article "2-Arachidonyl glyceryl ether" in Czech language version.

refsWebsite
Global rank Czech rank
4th place
8th place
2nd place
4th place
low place
low place

caymanchem.com

doi.org

dx.doi.org

  • HANUS, L.; ABU-LAFI, S.; FRIDE, E.; BREUER, A.; VOGEL, Z.; SHALEV, D.; KUSTANOVICH, I. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences. 2001, s. 3662–3665. DOI 10.1073/pnas.061029898. PMID 11259648. 
  • Oka S; TSUCHIE A; TOKUMURA A; MURAMATSU, Mayumi; SUHARA, Yoshitomo; TAKAYAMA, Hiroaki; WAKU, Keizo. Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem.. 2003, s. 1374–81. DOI 10.1046/j.1471-4159.2003.01804.x. PMID 12787057. 
  • Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett.. 2002, s. 294–8. DOI 10.1016/S0014-5793(02)02341-4. PMID 11904167. 
  • Richardson D, Ortori CA, Chapman V, Kendall DA, Barrett DA. Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal. Biochem.. 2007, s. 216–26. DOI 10.1016/j.ab.2006.10.039. PMID 17141174. 
  • Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J. Pharmacol. Exp. Ther.. 2005, s. 868–75. DOI 10.1124/jpet.105.085282. PMID 15901805. 
  • Duncan M, Millns P, Smart D, Wright JE, Kendall DA, Ralevic V. Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 Gi/o linked receptor. Br. J. Pharmacol.. 2004, s. 509–18. DOI 10.1038/sj.bjp.0705789. PMID 15148262. 
  • Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J. Pharmacol. Exp. Ther.. 2005, s. 828–38. DOI 10.1124/jpet.105.089474. PMID 16081674. 
  • Venderova K, Brown TM, Brotchie JM. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. Exp. Neurol.. 2005, s. 284–7. DOI 10.1016/j.expneurol.2005.02.012. PMID 15899265. 
  • Sun Y; ALEXANDER SP; GARLE MJ; GIBSON, C L; HEWITT, K; MURPHY, S P; KENDALL, D A. Cannabinoid activation of PPARα; a novel neuroprotective mechanism. Br. J. Pharmacol.. 2007, s. 734–43. DOI 10.1038/sj.bjp.0707478. PMID 17906680. 

nih.gov

ncbi.nlm.nih.gov

  • HANUS, L.; ABU-LAFI, S.; FRIDE, E.; BREUER, A.; VOGEL, Z.; SHALEV, D.; KUSTANOVICH, I. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences. 2001, s. 3662–3665. DOI 10.1073/pnas.061029898. PMID 11259648. 
  • Oka S; TSUCHIE A; TOKUMURA A; MURAMATSU, Mayumi; SUHARA, Yoshitomo; TAKAYAMA, Hiroaki; WAKU, Keizo. Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem.. 2003, s. 1374–81. DOI 10.1046/j.1471-4159.2003.01804.x. PMID 12787057. 
  • Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett.. 2002, s. 294–8. DOI 10.1016/S0014-5793(02)02341-4. PMID 11904167. 
  • Richardson D, Ortori CA, Chapman V, Kendall DA, Barrett DA. Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal. Biochem.. 2007, s. 216–26. DOI 10.1016/j.ab.2006.10.039. PMID 17141174. 
  • Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J. Pharmacol. Exp. Ther.. 2005, s. 868–75. DOI 10.1124/jpet.105.085282. PMID 15901805. 
  • Duncan M, Millns P, Smart D, Wright JE, Kendall DA, Ralevic V. Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 Gi/o linked receptor. Br. J. Pharmacol.. 2004, s. 509–18. DOI 10.1038/sj.bjp.0705789. PMID 15148262. 
  • Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J. Pharmacol. Exp. Ther.. 2005, s. 828–38. DOI 10.1124/jpet.105.089474. PMID 16081674. 
  • Laine K, Järvinen K, Mechoulam R, Breuer A, Järvinen T. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest. Ophthalmol. Vis. Sci.. 2002, s. 3216–22. PMID 12356827. 
  • Venderova K, Brown TM, Brotchie JM. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. Exp. Neurol.. 2005, s. 284–7. DOI 10.1016/j.expneurol.2005.02.012. PMID 15899265. 
  • Sun Y; ALEXANDER SP; GARLE MJ; GIBSON, C L; HEWITT, K; MURPHY, S P; KENDALL, D A. Cannabinoid activation of PPARα; a novel neuroprotective mechanism. Br. J. Pharmacol.. 2007, s. 734–43. DOI 10.1038/sj.bjp.0707478. PMID 17906680.